Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.60 0.11% 1,405.20 1,403.80 1,404.40 1,416.00 1,400.00 1,404.60 11,824,382 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 16.0 57,154

Gsk Share Discussion Threads

Showing 31201 to 31224 of 31675 messages
Chat Pages: Latest  1255  1254  1253  1252  1251  1250  1249  1248  1247  1246  1245  1244  Older
DateSubjectAuthorDiscuss
12/10/2022
12:56
blimey Addullla how do you know this sort of stuff...

Will it finish the day BLUE or RED?

netcurtains
12/10/2022
10:03
What about investors here sitting on a quarter of a million pounds paper losses,by the way GSK up 25p this morning will shortly be zero up .
abdullla
12/10/2022
10:02
Ali, I don't think you are alone in that boat!
tradermichael
12/10/2022
08:24
As my shares in haleon and GSK have dropped in value by over 14k I need GSK to get back to around £18 or haleon to rise to around £5 , both seem unlikely so will sit on them for as long as it takes
alibizzle
12/10/2022
07:51
And this time last year, $1.40 = £1, now, £1.10 = £1
tradermichael
12/10/2022
07:38
Over 40% of earnings in a strong currency.
patientcapital
12/10/2022
07:37
Great time to add
gla

charlie9038
12/10/2022
07:36
Interesting
netcurtains
11/10/2022
06:41
And this year it's on Wednesday 2 November. Expect outstanding performance!
tradermichael
11/10/2022
06:28
27th October 2021 was when 3rd quarter results came out last year
berny3
10/10/2022
18:32
When is next news expected here
ridingthewaves1
10/10/2022
08:25
RENE (LSE) produced ground breaking data , excellent
blackhorse23
09/10/2022
16:45
Alp - yes, a good point. And these advanced antibody treatments potentially bring strong opportunities to extend to other therapies.
tradermichael
09/10/2022
08:53
TM - To add to your post about late stage trials it should be noted that they can be used to increase potential patient exposure for later marketing (Phase IIIb trials) and Phase IV trials to explore more indications......... etc.
alphorn
09/10/2022
08:04
The third phase of clinical trials typically lasts between one and four years. FDA Approval: Once Phase 3 has concluded, the company studying the drug can submit a New Drug Application (NDA) or a biologics license application (BLA) for the treatment to the Food and Drug Administration (FDA).

Finally, on Phase 4, after a product receives FDA approval and is on the market for consumers to use, further clinical trials may continue to gather more information on side effects, risks, benefits, and best uses. These studies are known as post-marketing surveillance (PMS) trials.

Phase 4 trials usually include hundreds to a few thousand participants.

tradermichael
08/10/2022
18:06
How many phases are normally after phase 3?
And how long has average phase 3 take?

Cheers Net.

netcurtains
08/10/2022
17:33
'safety and tolerability profile' I would hope so - but does it work? That is the question.
alphorn
08/10/2022
17:11
This is all you need to know:

GSK PLC on Wednesday said its drug for metastatic non-squamous non-small cell lung cancer Jemperli, or dostarlimab, is advancing to a phase 3 trial following positive results.

Jemperli is an antibody approved for the treatment of endometrial cancer in the US and EU.

Non-squamous means flat cells do not look like a fish scale under a microscope.

Citing its phase 2 Perla study, the Brentford, west London-based pharmaceuticals firm said that the safety and tolerability profile of dostarlimab was consistent with previous clinical trials of similar regimens.

Further, in its Costar phase 2/3 trial, now advancing to phase 3, GSK stated that the trial met its pre-specified expansion criteria per protocol.

"These trials support the ambition for dostarlimab to become the backbone of our ongoing immuno-oncology-based research and development programme when used alone and in combination with standard of care and future novel cancer therapies, particularly in patients with currently limited treatment options," said Hesham Abdullah, Senior Vice President & Global Head of GSK's Oncology Development arm.

tradermichael
08/10/2022
15:40
'Forced Recession'..whats that all about!
paul planet earth
08/10/2022
11:16
Forced recession in the US, works well for big Pharma for obvious reasons, strong dollar, resilient earnings I could go on. Makes GSK one of the best plays around IMO. I have recently stated we will be back to £15+ over the next 6 months. One caveat being Russia going nuclear
pol123
07/10/2022
10:49
Its entirely probable, given third quarter 2022 results on Wednesday 2 November.

These are expected to show a strong performance, especially with the strong dollar vs the weak pound.

tradermichael
07/10/2022
09:53
That's a difficult one net as wider market conditions could keep it lower.
I think the company specific "bad news" has to be priced in so hopefully it slowly climbs back up. It would only need circa 3% a week from now to get to 1450 so it's possible.

tuftymatt
07/10/2022
09:47
Do you think this might break through 1450 by November?
netcurtains
06/10/2022
21:09
Try pressing filter button then tw@t!
paul planet earth
Chat Pages: Latest  1255  1254  1253  1252  1251  1250  1249  1248  1247  1246  1245  1244  Older
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 05:08:16